Cell Therapeutics has announced exciting results from a new class of platinum-based anti-tumour compounds, which demonstrated strong anti-tumour potency and activity as well as the ability to overcome cisplatin resistance in cancer cell lines.

The results demonstrated that the new compounds called bis-platinates demonstrated a stronger anti-tumour potency and activity compared to currently available platinum-based compounds.

According to CTI the new class of compounds are not limited by the relatively low therapeutic effect versus tolerance ratio and the frequent cases of drug resistance that plague other platinum-based compounds, such as cisplatin and oxaliplatin, which are cornerstones in the treatment of many cancers.

CTI chief medical officer Jack Singer said that platinum-based compounds are cornerstone agents in the treatment of very common cancers but resistance is common.

“The results are encouraging as they demonstrate that the bisplatinates are not only more effective than the current agents, but also capable of overcoming some forms of palatinate resistance,” Singer said.

Unlike approved platinum-based compounds, CTI’s new formulations contain two platinum atoms and work by binding to and damaging both strands of DNA, making it much more difficult for cancer cells to repair the damage.

Results demonstrated through cancer cell assays and animal tumour models showed greater cytotoxic potency and anti-tumour effectiveness, as well as a more than 200-fold increase in percent accumulation in tumour cells of the bisplatinum compounds when compared to cisplatin and oxaliplatin.